Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2019 Annual Meeting
The event will include a discussion of new data presented at the
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. For those who are unable to attend in person, a live webcast and replay of the presentations will be accessible here.
Zogenix is a global pharmaceutical company committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases. The company has two late-stage development programs underway: investigational drug FINTEPLA® (ZX008, fenfluramine oral solution), for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies, and MT1621, a novel substrate enhancement therapy for the treatment of TK2 deficiency, a rare genetic disorder. Zogenix’s New Drug Application for FINTEPLA for Dravet syndrome has been accepted for review by the
Senior Director, Corporate Communications
+1 (510) 788-8732 | email@example.com
+1 (646) 597-6987 | Andrew@lifesciadvisors.com
Source: Zogenix, Inc.